Parnax Lab Limited announced its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, following approval by the Board of Directors at their meeting held on February 13, 2026. The pharmaceutical company demonstrated strong operational performance across both standalone and consolidated operations during the third quarter of fiscal year 2026.

Consolidated Financial Performance

The company's consolidated operations showed robust growth momentum during Q3FY26. Revenue from operations reached ₹6,294.15 lakhs, representing a substantial 56.45% increase from ₹4,021.61 lakhs recorded in the corresponding quarter of the previous year. Total revenue, including other income, stood at ₹6,391.30 lakhs compared to ₹4,040.56 lakhs in Q3FY25.

Net profit after minority interest surged 124.29% to ₹271.47 lakhs in Q3FY26 from ₹121.02 lakhs in the same quarter last year. The company's earnings per share (basic) improved significantly to ₹2.37 from ₹1.06, reflecting the strong bottom-line performance.

Nine-Month Consolidated Results

For the nine months ended December 31, 2025, consolidated revenue from operations grew 29.01% to ₹17,891.89 lakhs compared to ₹13,869.93 lakhs in the corresponding period of the previous year. Net profit for the nine-month period increased 11.65% to ₹960.03 lakhs from ₹859.92 lakhs, demonstrating consistent profitability growth.

Standalone Financial Performance

The standalone operations also exhibited strong growth with revenue from operations reaching ₹270.82 lakhs in Q3FY26, marking a remarkable 174.58% increase from ₹98.63 lakhs in Q3FY25. Net profit for the quarter surged 349.43% to ₹70.91 lakhs compared to ₹15.78 lakhs in the previous year's corresponding quarter.

For the nine-month period, standalone revenue grew modestly by 3.15% to ₹637.68 lakhs, while net profit declined 2.76% to ₹143.74 lakhs from ₹147.82 lakhs in the previous year.

Exceptional Items and Tax Impact

The company reported exceptional expenses of ₹113.80 lakhs in consolidated results and ₹2.16 lakhs in standalone results for Q3FY26. These exceptional items primarily relate to incremental gratuity impact arising from changes in wage definition following the Government of India's notification of four Labour Codes on November 21, 2025.

The consolidated tax expense for Q3FY26 totaled ₹53.29 lakhs, comprising current tax of ₹60.60 lakhs and deferred tax benefit of ₹7.31 lakhs. The effective tax management contributed to the improved net profit margins.

Corporate Governance and Compliance

The financial results were reviewed by the Audit Committee and approved by the Board of Directors. C.N. Patel & Co., Chartered Accountants, conducted a limited review of both standalone and consolidated financial results. The company maintains a paid-up equity share capital of ₹1,148.56 lakhs with a face value of ₹10 per share.

Parnax Lab Limited operates primarily in the pharmaceutical formulations segment and continues to focus on strengthening its market position through operational excellence and strategic growth initiatives.